ADVERTISEMENT
Torrent Pharma Q4 Review: Motilal Oswal Maintains 'Neutral', Says Current Valuation Factors In Earnings Upside
Motilal Oswal maintains 'Neutral' stance on Torrent Pharma, but hikes target price
21 May 2025, 09:17 AM IST 
Torrent Pharma's India formulations revenue grew 12% YoY to Rs 15.5 billion. US generics grew 15.3% YoY to Rs 3 billion. (Photo Source: Freepik)
Torrent Pharma is readying itself to be in the first wave of launch of Semaglutide in India market. Its Curatio portfolio grew 18-19% YoY in FY25 and aspires to grow this business at higher rate in coming year. Torrent Pharma’s chronic portfolio in DF market grew 14% vs industry growth of 9% for the quarter.
I’m already a Subscriber
To continue reading this storySubscribe to Unlock & Enjoy your
Subscriber-Only benefits
Subscriber-Only benefits
Choose a plan
Renews automatically. Cancel anytime.
As a Subscriber you get
Access to
Stories
Curated
Newsletters
20,000+
Research Reports
Priority Pass
to Special Events
Ad-Lite
Experience
Subscriber-Only
Rewards
NDTV Profit
Exclusive Stories
Full Access to
NDTV Profit App
Access to
Stories20,000+
Research Reports
Ad-Lite
Experience
NDTV Profit
Exclusive Stories
Curated
Newsletters
Priority Pass
to Special Events
Subscriber-Only
Rewards
Full Access to
NDTV Profit App
Still Not convinced ? Know More
